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RESEARCH ARTICLE Open Access
Validation of the post sleep questionnaire for
assessing subjects with restless legs syndrome:
results from two double-blind, multicenter,
placebo-controlled clinical trials
Daniel M Canafax1, Abhijeet Bhanegaonkar2, Murtuza Bharmal3,4 and Michael Calloway5*
Abstract
Background: Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these
symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials
investigating RLS treatments. The objective of this study was to validate a new measure, the Post Sleep
Questionnaire (PSQ), to assess sleep dysfunction in subjects with moderate-to-severe RLS symptoms.
Methods: Pooled data were analyzed from two 12-week, randomized, placebo-controlled trials of gabapentin
enacarbil (N = 540). At baseline and Week 12, subjects completed the PSQ and other validated health surveys: IRLS
Rating Scale, Clinical Global Impression of Improvement (CGI-I), Profile of Mood States (POMS), Medical Outcomes
Study Scale-Sleep (MOS-Sleep), and RLS-Quality of Life (RLSQoL). Pooled data were used post hoc to examine the
convergent, divergent, known-group validity and the responsiveness of the PSQ.
Results: Convergent validity was demonstrated by significant correlations between baseline PSQ items and total
scores of IRLS, POMS, RLSQoL, and the MOS-Sleep Scale (p ≤ 0.007 each). Divergent validity was demonstrated
through the lack of significant correlations between PSQ items and demographic characteristics. Correlations (p <
0.0001) between RLS severity groups and PSQ items demonstrated known-group validity. Mean changes in
investigator- and subject-rated CGI-I scores for each PSQ item (p < 0.0001) demonstrated the PSQ’s responsiveness
to patient change as reported by their care provider.
Conclusions: Although these analyses were potentially limited by the use of clinical trial data and not prospective
data from a study conducted solely for validation purposes, the PSQ demonstrated robust psychometric properties
and is a valid instrument for assessing sleep and sleep improvements in subjects with moderate-to-severe RLS
symptoms.
Trial Registration: This study analyzed data from two registered trials, NCT00298623 and NCT00365352.
Background
Restless Legs Syndrome (RLS) is a sensorimotor disorder
that can substantially disrupt sleep. It affects 5-10% of
the general population [1], predominantly women [1,2],
and has been characterized as chronic in individuals with
moderate-to-severe symptoms requiring treatment [3].
The criteria that define RLS include an urge to move the
legs due to unpleasant or uncomfortable sensations
during periods of rest, the relief of symptoms through leg
movements, and symptoms that follow a distinct circa-
dian pattern [3]. The onset of RLS symptoms typically
begin in the late evening and may persist through the
night time hours. Thus, the primary morbidity in RLS is
sleep disruption, the major reason patients cite for con-
sulting their physicians [2,3].
Sleep-related problems, such as trouble initiating or
maintaining sleep and experiencing disturbed, non-rest-
ful or non-refreshing sleep, are more prevalent in
patients with RLS than in those without RLS [4]. Nearly
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90% of patients with RLS experience at least 1 sleep-
associated symptom and over 40% of patients identified
sleep-associated issues as the most bothersome RLS-
related symptom [5]. Nearly 70% of patients with twice
weekly RLS symptoms needed more than 30 minutes to
fall asleep and 60% had more than 3 awakenings per
night. On average, patients with severe RLS symptoms
sleep only 4 to 5 hours per night [5].
Because of the subjective nature of RLS symptoms and
the impact of these symptoms on sleep, patient-reported
outcomes (PROs) play a prominent role as study end-
points in clinical trials investigating RLS treatments.
However, for PROs to be credible, they must be sub-
jected to a rigorous inspection of their measurement
properties using measurement theory and standard psy-
chometric assessments. While there were several pre-
existing sleep instruments to choose from (i.e., MOS
Sleep Questionnaire) most were limited in their use in
RLS research because they were not disease specific, or
were more difficult to administer within a clinical trial
setting (i.e., clinician-administered). The hope was to be
more responsive to the Food and Drug Administration’s
(FDA) recently emphasized expectations around patient
reported outcome measures and the need to demon-
strate the validity and reliability of such scales when
used to measure endpoints in clinical trials [6].
The Post Sleep Questionnaire (PSQ) is a, 5-item PRO
instrument designed to evaluate sleep disturbance in
subjects with RLS. This study was a post-hoc evaluation
of the validity of the PSQ, Version 2, using data from 2
well-controlled clinical trials in subjects with moderate-
to-severe RLS [7,8].
Methods
Data source
This study used pooled data from two 12-week, multi-
center, randomized, double-blind, placebo-controlled
clinical trials (XenoPort, Inc. protocols XP052 [Clinical-
Trials.gov Identifier NCT00298623] and XP053 [Clini-
calTrials.gov Identifier NCT00365352]) that evaluated
the efficacy and tolerability of gabapentin enacarbil
(GEn) for the treatment of moderate-to-severe primary
RLS [7,8]. The co-primary endpoints for the 1200 mg
and placebo groups in both studies were the reduction
in total IRLS score from baseline to Week 12 on the
International Restless Legs Scale (IRLS) [9] and the pro-
portion of responders rated by investigators as “very
much improved” or “much improved” on the Clinical
Global Impression-Improvement [CGI-I] scale) [10].
The secondary endpoints evaluated subject-rated
improvements in sleep, mood, and quality of life.
The studies were of similar design. Subjects were ran-
domly assigned for 12 weeks of treatment to GEn 1200
mg or matching placebo (XP052, XP053), with study
XP053 also examining a third treatment group, GEn 600
mg, as a secondary endpoint compared with placebo.
These studies demonstrated statistically significant effi-
cacy with both GEn doses compared with placebo for
reduction of RLS symptoms and improvements in sleep,
mood, and quality of life [7,8].
Study population
Study methodologies have been published elsewhere
[7,8]. Briefly, eligible subjects were ≥18 years of age,
diagnosed with primary RLS, having RLS symptoms ≥15
nights of the month prior to study enrollement and for
≥4 of 7 consecutive nights in the week prior to their
baseline assessment, and had a total RLS severity score
of ≥15 (i.e., moderate-to-severe severity). If subjects
were receiving RLS treatment at screening, then they
must have had a symptom frequency of ≥15 nights per
month prior to treatment initiation. A 2-week washout
period prior to the baseline assessments was required
for dopamine agonists, gabapentin, opioids, and
benzodiazepines.
Subjects with non-RLS-related sleep disorders (e.g.,
sleep apnea), a history of RLS symptom augmentation
or early-morning rebound with previous dopamine-ago-
nist treatment, neurological disease or movement disor-
ders other than RLS (e.g., diabetic neuropathy,
Parkinson’s disease, multiple sclerosis, dyskinesias, and
dystonias), or other medical conditions that could con-
found study results were excluded.
PSQ
Figure 1 displays the 5 items comprising the PSQ, the
sleep domains corresponding to each question, the asso-
ciated response categories, and the scoring for each. The
PSQ was developed to evaluate sleep disturbance in sub-
jects with primary RLS over the past weeks using 4
Likert-type scale questions and 1 quantitative, open-
ended question. The PSQ assesses several single-item
sleep domains, including overall sleep quality, overall
daytime functioning, frequency of night time RLS symp-
toms, and RLS-related sleep disturbances and latency.
Higher PSQ scores indicate worse sleep.
Validated sleep instruments
Seven PRO instruments were completed as part of the
clinical trials assessments. Five of the instruments were
previously validated and were used in the present study
to validate the PSQ: 1) IRLS Rating Scale comprises 10
questions that assess symptom severity and frequency
on a 40-point scale (0 = no symptom; 40 = very severe
symptoms); subjects were also classified into RLS symp-
tom severity categories using the IRLS total score (mild
= 0-10, moderate = 11-20, severe = 21-30, and very
severe ≥31) [11]; 2) investigator- and subject-rated CGI-
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I, evaluates improvements in any disease on a 7-point
scale (1 = “very much improved"; 7 = “very much
worse”) [10]; 3) Profile of Mood States (POMS) is a 30-
item scale that assesses mood in 6 domains and 1 total
overall mood score, with higher scores indicating a
more negative mood state [12]; 4) Medical Outcomes
Study (MOS) Scale-Sleep assesses sleep constructs,
including sleep initiation, maintenance, perceived ade-
quacy, somnolence, respiratory impairments, and regu-
larity in subjects with health comorbidities, such as RLS
[13-16]; and 5) RLS Quality of Life Questionnaire
(RLSQoL), a 100-point scale that assesses the direct
impact of RLS on the daily life, emotional well-being,
social life, and work-life of the subject, with lower scores
PSQ Item Domains Assessed Responses Score 
PSQ1: What was the overall 
quality of your sleep during the 
past week? 
Sleep Qualityz Excellent (I slept well 
without Waking and 
awoke fresh) 
 
Reasonable (I slept 
moderately well; I awoke 
rarely and went back to 
sleep without difficulty; I 
awoke feeling fine) 
 
Poor (I slept poorly and 
awoke frequently; I lay 
awake a lot of the night; I 
awoke feeling tired) 
1 
 
 
 
 
2 
 
 
 
 
3 
PSQ2: Over the last week, how 
would you rate your ability to 
function during the day? 
Daytime 
Functioning 
Excellent (I was alert and 
able to focus well on my 
daily activities) 
 
Good (I completed my 
daily activities with 
reasonable focus) 
 
Moderate (I 
accomplished most of 
what I had planned for 
the day, but felt drowsy 
and unable to focus well 
on my tasks) 
 
Poor (I was tired all day 
and felt like taking a nap 
or took at least 1 nap) 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
PSQ3: How often did you have 
RLS symptoms at night during 
the past week? 
Nights with RLS 
symptoms 
_____ nights 0 to 7 
If you did not have RLS symptoms on any night during the past week (your response                      Score PSQ4 and  
to question 3 was 0), then skip questions 4 and 5 below                                                                    PSQ5 as 0;   ‘No  
                                                                                                                                                            RLS symptom’ 
PSQ4: On those nights during 
the last week when you 
experienced RLS symptoms, 
how often did you wake during 
the night because of the RLS 
symptoms? 
RLS-related Sleep 
Disturbance 
 
0 times 
1-2 times 
3-4 times 
5 or more times 
 
1 
2 
3 
4 
PSQ5: On those nights when 
you experienced RLS 
symptoms, how long were you 
awake during the night because 
of the RLS symptoms? 
RLS-related Sleep 
Latency 
Did not wake-up 
Less than 1 hour 
1 hour to less than 2 hours 
2 hours to less than 3 hours 
3 or more hours 
1 
2 
3 
4 
5 
Figure 1 The 5-item PSQ with assessed domains, possible responses, and item scores. Higher scores indicate greater sleep difficulties
associated with RLS.
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indicating better quality of life [17,18]. The remaining 2
instruments were diaries that provided important sub-
ject response information: 1) the 24-hour RLS Record
assesses the frequency of RLS symptoms in half-hour
increments during a 24-hour period and 2) the 7-Day
RLS Symptom Diary assesses the frequency of nightly
symptoms over a 1-week period.
Analyses
Analyses were conducted on pooled data irrespective of
treatment assignment, as baseline assessments were used
to generate the psychometric indices. Data from 540 sub-
jects were included in these analyses: 220 from XP052 and
320 from XP053. As shown in Table 1, there were no
major differences between the 2 study populations at base-
line in terms of age, gender, ethnicity, or disease severity.
The following psychometric properties were assessed.
Convergent validity
Convergent validity, the extent of agreement between 2
scales that measure similar domains or criteria that are
linked with the domain of interest, was evaluated using
the nonparametric Spearman-rank correlation coeffi-
cient. Convergent validity is accepted when the correla-
tion estimates are in the correct theoretical direction
[19] and are statistically significant. If correlation coeffi-
cients are statistically significant, Cohen [20] describes
correlations of 0.1 as small, 0.3 as medium, and ≥0.5 as
large convergence. Convergent validity for the PSQ was
determined by correlating the PSQ item scores with the
total scores from the IRLS, RLSQoL, and POMS, and
the 4 individual domain scores of the MOS-Sleep scale.
Individual PSQ item scores were also correlated with
similar items from daily diaries that captured RLS-related
symptoms and sleep: PSQ Item 3 (nights with RLS symp-
toms) score and nights with RLS symptoms score from
the 7-Day RLS Symptom Diary, PSQ Item 4 (RLS-related
sleep disturbance) with number of RLS-related awakenings
score from the 24-Hour RLS Symptom Diary, and PSQ
Item 5 (RLS-related sleep latency) with the RLS-related
sleep latency score from the 24-Hour RLS Record.
Divergent validity
An instrument demonstrates divergent validity when it
shows a lack of statistical association with other instru-
ments or related variables (e.g., demographic character-
istics) unrelated to the focus instrument. This study was
limited in the choice of instruments to assess divergent
validity because it utilized only the instruments included
in the clinical trials [7,8] that were used to measure the
effects of RLS treatment. To demonstrate divergent
validity of the PSQ, we assessed correlations between
the baseline PSQ item scores and three demographic
variables: ethnicity, race, and gender. Because there was
no theoretical basis to expect a relationship between
sleep problems and these demographic variables, a lack
of correlation would demonstrate that subjects with dif-
ferent demographic characteristics do not interpret the
PSQ items differently. Cramer’s V statistic was used to
assess their associations [21], because this involved cor-
relating a nominally scaled variable (i.e., 0 = Male, 1 =
Female) with continuous variables. Cramer’s V estimates
range from 0 to 1, with low scores indicating poor asso-
ciation and demonstrating divergent validity.
Known-group validity
Known-group validity, or predictive validity, is the ability
of a scale or scale items to statistically discriminate
respondents in ways expected (predicted) as a result of
independent assessments. The known groups in the cur-
rent study were based on RLS symptom severity, as
determined by the IRLS total score. Sleep qualities mea-
sured by the PSQ are expected to be most pronounced
for persons with severe symptoms. Baseline PSQ scores
were compared across severity groups using the Krus-
kal-Wallis test [22].
Table 1 Baseline demographic and characteristics of
enrolled subjects from two clinical trials conducted in
subjects with primary RLS
Characteristic XP052
(n = 220)
XP053
(n = 320)
All
(n = 540)2
Age
Mean (SD) 51.5 (12.75) 49.3 (12.55) 50.2 (12.66)
Female (n, %) 131 (59.5%) 189 (59.1%) 320 (59.3%)
Race (n, %)
White or Caucasian 212 (96.4) 303 (94.7) 515 (95.4)
Black or African-American 5 (2.3) 5 (1.6) 10 (1.9)
Other 3 (1.3) 12 (3.7) 15 (2.7)
Ethnicity (n, %)
Hispanic or Latino 8 (3.6) 25 (7.8) 33 (6.1)
Non-Hispanic or Latino 212 (96.4) 295 (92.2) 507 (93.9)
Treatment (n, %)
1200 mg 113 (51.4) 111 (34.7) 224 (41.5)
600 mg 0 113 (35.3) 113 (20.9)
Placebo 107 (48.6) 96 (30.0) 203 (37.6)
RLS Severity (n, %)1
Mild 0 0 0
Moderate 82 (37.3) 102 (31.9) 184 (34.1)
Severe 121 (55.0) 193 (60.3) 314 (58.1)
Very severe 17 (7.7) 25 (7.8) 42 (7.8)
RLS, Restless Legs Syndrome; SD, standard deviation.
1RLS Disease Severity based on International Restless Legs Rating Scale Total
Score, where mild = 0-10, moderate = 11-20, severe = 21-30, and very severe
>30.
2In the original clinical trials; there were a total of 544 subjects. In this study
we used the Post Sleep Questionnaire (PSQ) validation sample, which includes
only those who completed the PSQ at Baseline (N = 540) and Week 12 (N =
451).
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Responsiveness
Responsiveness means that the PSQ item scores will
change in direction and magnitude with changes experi-
enced by the responders. In this case, responsiveness was
demonstrated if relationships between changes in the
investigator- and subject-rated CGI-I assessments and
changes in PSQ scores over time were in the same direc-
tion and statistically significant [15]. Change from baseline
in individual PSQ items were compared with subject
symptom changes as measured by the CGI-I using the
Kruskal-Wallis test. Among all subjects in the clinical
trials [7,8], only a few experienced worsening of symptoms
over time; as a result, the responsiveness analysis was con-
ducted by re-categorizing subjects reporting ‘minimally
worse’, ‘much worse’ and ‘very much worse’ into 1 cate-
gory of ‘worse’. Guyatt’s statistic, a measure of test-retest
reliability or responsiveness to change, which is the ratio
of the mean change for each category divided by the stan-
dard deviation for the no change group, was estimated. An
instrument with an absolute value of ≥0.20 for Guyatt’s
statistic has acceptable responsiveness and a value of ≥1.00
is considered highly responsive to change [23,24].
Results
Subject characteristics
Of 544 total subjects, 540 and 451 completed the PSQ
at Baseline and Week 12, respectively, and were
included in the analysis. Table 1 shows that the baseline
mean age of subjects was approximately 50 years, most
subjects were non-Hispanic, white, and female. About
92% had moderate or severe RLS symptoms and 8% had
very severe symptoms.
PSQ results
The mean scores for PSQ items indicate that most sub-
jects improved over the 12-week study, and most of the
improvements occurred by Week 4 (Table 2). For sleep
quality, the percentage of subjects reporting their sleep
quality as “excellent” increased by approximately 20% by
Week 12. Daytime functioning showed similar positive
gains, with 4.5 times as many subjects reporting their
daytime functioning as “excellent” at Week 12 compared
with baseline. Similar improvements in frequency of
nighttime RLS symptoms, RLS-related sleep disturbances
and sleep latency over the 12 weeks were observed.
Convergent validity
Table 3 shows the Spearman rank correlation coeffi-
cients and the probability of each PSQ item based on
the total scores of the IRLS, RLSQoL, and POMS. All
correlations between the IRLS total score and each PSQ
item were statistically significant, ranging from 0.25 to
0.49 (p > 0.0001, each). The strength of the associations
showed moderate to moderately high convergence. The
overall POMS total score had statistically significant cor-
relations with the PSQ items, except for the item “nights
with RLS symptoms”. The correlations ranged from 0.04
to 0.48. All but 1 of the correlations were small in size;
daytime functioning was moderately high. For the indi-
vidual POMS items, 22 of 35 correlations were statisti-
cally significant (p < 0.05 each; data not shown). The
correlations between the RLSQoL total score and the
PSQ items were also statistically significant. The correla-
tion coefficients ranged from -0.12 to -0.57 (p < 0.01
each). The convergence was large for daytime function-
ing, moderate for sleep quality, and small for all others.
The correlations between the MOS-Sleep scale
domains and the PSQ items are provided in Table 4.
The correlation coefficients ranged from -0.46 to 0.49;
18 of 20 correlations were statistically significant (p <
0.02). Of the 20 correlations, 9 had moderate to moder-
ately large coefficients. Moderately high convergence
was seen between the PSQ sleep quality item and the
MOS sleep disturbance domain (higher sleep distur-
bance, lower sleep quality) and sleep adequacy (higher
sleep quality, higher sleep adequacy), between PSQ day-
time functioning and MOS daytime somnolence domain
(worse functioning, worse somnolence), between PSQ
sleep latency and MOS sleep disturbance domain
(higher sleep latency, higher sleep disturbance). The cor-
relations of the PSQ item nights with RLS symptoms
were statistically significant with MOS sleep domains,
but showed small convergence with MOS sleep distur-
bance, adequacy and quantity domains.
The 7-day RLS Symptom Diary significantly correlated
with the PSQ item #3 nights with RLS symptoms (r =
0.47; p < 0.0001; data not shown). The correlation between
the 24-hour RLS Symptom Record Diary and the PSQ
items RLS-related sleep disturbance and RLS-related sleep
latency were 0.17 and 0.27, respectively (p < 0.0001, both).
Divergent validity
None of the correlation estimates from Cramer’s V for
any PSQ item baseline score across the 3 demographic
variables (i.e., race, gender and ethnicity) were larger
than 0.13 (data not shown) and none approached statis-
tical significance, thereby demonstrating divergent valid-
ity. For race, the correlation estimates ranged from 0.05
for sleep latency to 0.13 for sleep disturbance. The
respective estimates for ethnicity ranged from 0.02 to
0.07, and for gender, the range was 0.05 to 0.12.
Known-group validity
Positive and statistically significant differences (p <
0.0001, each) were found between baseline PSQ scores
and the RLS severity groups moderate, severe, and very
severe (Table 5). The estimates were linear across the
severity groups with very severe RLS subjects having
Canafax et al. BMC Neurology 2011, 11:48
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Table 2 Subject responses and mean scores for PSQ items
Overall sleep quality
Excellent, n (%) 3 (0.6) 98 (20.1) 78 (16.6) 91 (20.2)
Reasonable, n (%) 209 (38.7) 294 (60.2) 293 (62.2) 279 (61.9)
Poor, n (%) 328 (60.7) 96 (19.7) 100 (21.2) 81 (18.0)
Mean PSQ score (SD) 2.602 (0.501) 1.996 (0.631) 2.047 (0.614) 1.978 (0.618)
Daytime functioning
Excellent, n (%) 35 (6.5) 146 (29.9) 163 (34.6) 159 (35.3)
Good, n (%) 240 (44.4) 238 (48.8) 222 (47.1) 220 (48.8)
Moderate, n (%) 230 (42.6) 95 (19.5) 80 (17.0) 63 (14.0)
Poor, n (%) 35 (6.5) 9 (1.8) 6 (1.3) 9 (2.0)
Mean PSQ score (SD) 2.491 (0.714) 1.932 (0.751) 1.849 (0.738) 1.827 (0.737)
Frequency of nighttime RLS symptoms
0 0 83 (17.0) 99 (21.0) 109 (24.2)
1 9 (1.7) 144 (29.5) 133 (28.2) 126 (27.9)
2 46 (8.5) 107 (21.9) 103 (21.9) 77 (17.1)
3 187 (34.6) 61 (12.5) 57 (12.1) 67 (14.9)
4 298 (55.2) 93 (19.1) 79 (16.8) 72 (16.0)
Mean PSQ score (SD) 3.433 (0.719) 1.871 (1.360) 1.754 (1.363) 1.705 (1.397)
Frequency of RLS-related sleep disturbance
No RLS symptoms 0 83 (17.0) 99 (21.0) 109 (24.2)
0 times 59 (10.9) 135 (27.7) 111 (23.6) 115 (25.5)
1-2 times 262 (48.5) 203 (41.6) 205 (43.5) 184 (40.8)
3-4 times 163 (30.2) 49 (10.0) 48 (10.2) 36 (8.0)
≥5 times 56 (10.4) 18 (3.7) 8 (1.7) 7 (1.6)
Mean PSQ score (SD) 2.400 (0.817) 1.557 (1.006) 1.480 (0.989) 1.373 (0.986)
RLS-related sleep latency (time awake)
No RLS symptoms 0 83 (17.0) 99 (21.0) 109 (24.2)
Did not wake-up 59 (10.9) 135 (27.7) 111 (23.6) 115 (25.5)
<1 hour 240 (44.4) 176 (36.1) 180 (38.2) 160 (35.5)
1-<2 hours 133 (24.6) 67 (13.7) 57 (12.1) 45 (10.0)
2-<3 hours 74 (13.7) 12 (2.5) 18 (3.8) 12 (2.7)
≥3 hours 34 (6.3) 15 (3.1) 6 (1.3) 10 (2.2)
Mean PSQ score (SD) 2.600 (1.055) 1.662 (1.165) 1.580 (1.136) 1.481 (1.167)
PSQ, Post Sleep Questionnaire; RLS, Restless Legs Syndrome; SD, standard deviation.
1All responses were based on experiences during the previous week.
Higher PSQ scores correspond to worse symptoms.
Table 3 Convergent validity: PSQ item correlations at baseline with IRLS, POMS, and RLSQoL total scores
PSQ item IRLS total score
(n = 540)
POMS overall mood score
(n = 539)
RLSQoL total score
(n = 540)
Correlation (p-value) Correlation (p-value) Correlation (p-value)
Sleep quality 0.4635 (<0.0001) 0.2319 (<0.0001) -0.2986 (<0.0001)
Daytime functioning 0.4890 (<0.0001) 0.4818 (<0.0001) -0.5663 (<0.0001)
Nights with RLS symptoms 0.2509 (<0.0001) 0.0388 (0.3690) -0.1154 (0.0073)
RLS-related sleep disturbance 0.3186 (<0.0001) 0.1174 (0.0063) -0.2371 (<0.0001)
RLS-related sleep latency 0.3725 (<0.0001) 0.1205 (0.0051) -0.2870 (<0.0001)
IRLS, International Restless Legs Rating Scale; POMS, Profile of Mood States; PSQ, Post Sleep Questionnaire; RLSQoL, Restless Legs Syndrome Quality of Life
Questionnaire.
Spearman Correlation coefficients.
Higher PSQ scores correspond to worse RLS symptoms.
Higher IRLS Total scores correspond to higher severity of restless leg syndrome symptoms.
Higher POMS scores correspond to increased negative mood affect.
Higher RLS Quality of life scores correspond to better quality of life.
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worse PSQ scores than subjects with severe RLS and
subjects with severe RLS having worse PSQ scores than
subjects with moderate RLS.
Responsiveness
The mean change in PSQ scores from baseline to Week
12 indicate that improvements in sleep were achieved
and scores were significantly improved across each of
the investigator- and subject-rated CGI-I categories
(Tables 6 and 7, respectively). The largest change was
among those subjects judged by the clinician as being
“very much improved” followed by “much improved”,
“minimally improved”, “no change”, and finally “worse.”
The magnitude of the effect size for change in PSQ
scores from baseline also followed the above linear
order (data not shown). The magnitude of Guyatt’s sta-
tistic was moderate to large, ranging from 0.00 to 3.46
among improved subjects. Of the 50 coefficients, 7 did
not meet the acceptable cutpoint of 0.20 or greater and
all but 1 of the 7 was in the “worse” category. Addition-
ally, 11 of the 50 coefficients were >1, indicating a
highly responsive measure.
Discussion
This post hoc psychometric evaluation of an investiga-
tor-developed PRO instrument used data from 2 rando-
mized, double-blind, placebo-controlled trials conducted
in subjects with moderate-to-severe primary RLS to
examine the validity of the PSQ in assessing RLS-related
sleep disturbance and treatment improvements. The
parent studies indicated that the PSQ scores showed
improved sleep in subjects with RLS symptoms who
received active RLS treatment compared with placebo
[7,8].
To verify the validity of the PSQ, several measurement
properties were evaluated. The PSQ’s convergent validity
was estimated using correlations between the overall
RLS symptom impact score, as assessed with the IRLS,
and the individual PSQ items. These correlation esti-
mates were all statistically significant and positive (i.e.,
worse symptom impact with worse sleep status). All
PSQ items scores had moderate convergence with over-
all RLS symptom impact, except for the PSQ item
“nights with RLS symptoms”, which had a lower
convergence.
Convergent validity was also assessed using the MOS
Sleep Scale. Nearly half of the correlations with the
MOS-Sleep Scale sleep domains showed moderate to
moderately high convergence. Two PSQ items, nights
with RLS symptoms and RLS-related sleep latency,
showed little convergence with the MOS daytime som-
nolence domain. The PSQ sleep quality domain had
Table 4 Convergent validity: PSQ items and MOS Sleep domains at baseline
PSQ item MOS Sleep Domain Scores
Daytime somnolence
n = 540
Sleep disturbance
n = 540
Sleep adequacy
n = 540
Sleep quantity
n = 539
Correlation
(p-value)
Correlation
(p-value)
Correlation
(p-value)
Correlation
(p-value)
Sleep quality 0.1856 (<0.0001) 0.4878 (<0.0001) -0.4635 (<0.0001) -0.3827 (<0.0001)
Daytime functioning 0.4290 (<0.0001) 0.3027 (<0.0001) -0.4084 (<0.0001) -0.2287 (<0.0001)
Nights with RLS symptoms 0.0458 (0.2881) 0.1025 (0.0172) -0.1537 (0.0003) -0.1207 (0.0050)
RLS-related sleep disturbance 0.1369 (0.0014) 0.3158 (<0.0001) -0.2188 (<0.0001) -0.2742 (<0.0001)
RLS-related sleep latency 0.0633 (0.1420) 0.4290 (<0.0001) -0.2083 (<0.0001) -0.3798 (<0.0001)
MOS, Medical Outcomes Study; PSQ, Post Sleep Questionnaire; RLS, restless legs syndrome.
Spearman Correlation coefficients.
Higher PSQ scores correspond to worse symptoms.
Higher MOS Daytime Somnolence scores and MOS Sleep Disturbance scores correspond to worse symptoms.
Higher MOS Sleep Adequacy scores and MOS Sleep Quantity scores correspond to better symptoms.
Table 5 Known-group validity PSQ items and RLS disease
severity as assessed by IRLS total score at baseline
PSQ item score, mean
(SD)
RLS disease severity p-
value
Moderate
n = 184
Severe
n = 314
Very
Severe
n = 42
Sleep quality 2.342
(0.509)
2.710
(0.454)
2.929
(0.261)
<0.0001
Daytime functioning 2.125
(0.619)
2.611
(0.651)
3.190
(0.740)
<0.0001
Nights with RLS
symptoms
3.228
(0.777)
3.535
(0.664)
3.571
(0.668)
<0.0001
RLS-related sleep
disturbance
2.136
(0.774)
2.465
(0.792)
3.071
(0.712)
<0.0001
RLS-related sleep latency 2.190
(0.869)
2.720
(1.035)
3.500
(1.174)
<0.0001
IRLS, International Restless Legs Rating Scale; PSQ, Post Sleep Questionnaire;
RLS, Restless Legs Syndrome; SD, standard deviation.
Higher PSQ scores correspond to worse symptoms.
p-value is based on Kruskal-Wallis test.
RLS Disease Severity based on IRLS Total Score, where mild = 0-10, moderate
= 11-20, severe = 21-30, and very severe >30.
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Table 6 Responsiveness: mean change from baseline in PSQ item scores and Guyatt’s statistic by investigator-rated
CGI-I at Week 12
Investigator-rated CGI-I
PSQ domains Very Much
Improved
n = 173
Much Improved
n = 126
Minimally Improved
n = 64
No Change
n = 73
Worsen
n = 7
p-value
Sleep quality
Mean delta (SD) -0.92 (0.74) -0.67 (0.63) -0.34 (0.60) -0.14 (0.56) 0.14 (0.38) <0.0001
Guyatt’s statistic 1.64 1.19 0.61 0.24 0.25
Daytime functioning
Mean delta (SD) -1.03 (0.91) -0.62 (0.77) -0.34 (0.76) -0.15 (0.78) 0.14 (0.38) <0.0001
Guyatt’s statistic 1.33 0.80 0.44 0.19 0.18
Nights with RLS symptoms
Mean delta (SD) -2.71 (1.03) -1.75 (1.20) -0.97 (1.10) -0.26 (0.94) 0.57 (0.53) <0.0001
Guyatt’s statistic 2.87 1.86 1.03 0.28 0.61
RLS-related sleep disturbance
Mean delta (SD) -1.72 (1.14) -0.80 (0.96) -0.58 (0.83) -0.25 (0.95) -1.14 (1.07) <0.0001
Guyatt’s statistic 1.81 0.84 0.61 0.26 1.20
RLS-related sleep latency
Mean delta (SD) -1.82 (1.47) -0.80 (1.18) -0.69 (1.40) -0.19 (1.09) -1.29 (0.95) <0.0001
Guyatt’s statistic 1.67 0.74 0.63 0.18 1.18
CGI-I, Clinical Global Impression-Improvement, Investigator-rated; PSQ = Post Sleep Questionnaire; SD, standard deviation.
Higher PSQ scores correspond to worse symptoms.
Mean delta is change from baseline to Week 12.
p-value is based on Kruskal-Wallis test.
Guyatt’s statistic is the ratio of the mean change score for each category of subjects divided by the standard deviation for the no change group.
Table 7 Responsiveness: mean change from baseline in PSQ item scores, effect size, and Guyatt’s statistic by subject-
rated CGI-I at Week 12
Subject-rated Clinical Global Impression of Change
PSQ domains Very Much
Improved
n = 175
Much Improved
n = 130
Minimally Improved
n = 61
No Change
n = 65
Worse
n = 15
p-value
Sleep quality
Mean delta (SD) -0.92 (0.77) -0.68 (0.60) -0.31 (0.59) -0.14 (0.56) 0.00 (0.38) <0.0001
Guyatt’s statistic 1.66 1.23 0.56 0.25 0.00
Daytime functioning
Mean delta (SD) -1.01 (0.92) -0.68 (0.77) -0.33 (0.60) -0.05 (0.80) -0.13 (0.74) <0.0001
Guyatt’s statistic 1.27 0.85 0.41 0.06 0.17
Nights with RLS symptoms
Mean selta (SD) -2.74 (0.99) -1.70 (1.22) -0.93 (1.06) -0.25 (0.79) 0.00 (1.41) <0.0001
Guyatt’s statistic 3.46 2.15 1.18 0.31 0.00
RLS-related sleep disturbance
Mean delta (SD) -1.67 (1.15) -0.89 (1.01) -0.48 (0.74) -0.32 (0.94) -0.47 (1.19) <0.0001
Guyatt’s statistic 1.78 0.95 0.51 0.34 0.50
RLS-related sleep latency
Mean delta (SD) -1.82 (1.41) -0.86 (1.35) -0.38 (1.20) -0.32 (1.00) -0.73 (1.44) <0.0001
Guyatt’s statistic 1.82 0.86 0.38 0.32 0.73
CGI-I, Clinical Global Impression-Improvement, subject-rated; SD = Standard Deviation
Mean delta is change from baseline to Week 12
p-value is based on Kruskal-Wallis test
Effect size based on Cohen’s d is the difference in the mean score/pooled standard deviation.
Guyatt’s statistic is the ratio of the mean change score for each category of subjects divided by the standard deviation for the no change group.
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sufficient convergence with the MOS sleep disturbance,
sleep adequacy and sleep quantity domains. The PSQ
daytime functioning item had sufficient convergence
with all the MOS domains. The PSQ item, RLS-related
sleep latency, had sufficient convergence with MOS
sleep domains, except daytime somnolence. Taken
together, these data suggest that the PSQ items had ade-
quate convergence with the most pertinent MOS sleep
domains.
Validity can also be shown via divergence with scales
intended to measure other concepts. We found no
strong associations across the 3 demographic variables
of race, ethnicity and gender with the PSQ items. While
demographics are not traditionally used for assessing
divergent validity, we were limited to using the data col-
lected in the trials. Given that, these findings clearly and
robustly demonstrate that the PSQ results do not
include systematic measurement errors that could be
associated with personal attributes.
The PSQ results showed a consistent and robust abil-
ity to discriminate between RLS severity groups in a
known-group validity analysis. All estimates were linear
across the severity groups with increasingly worse sleep
outcomes found in progressively worse symptom groups.
The PSQ was found to provide reliable results; for exam-
ple, the PSQ was responsive to treatment differences over
12 weeks, and the findings were consistent regardless of
whether the investigator or the subject rated the improve-
ment, as indicated by the clinician and the patient rated
CGI-Is. Further, the changes were seen regardless of treat-
ment assignment, indicating that the PSQ is sensitive to
small clinical changes over the course of treatment.
Guyatt’s statistic, an indication of responsiveness to
change, was acceptably strong in all responder categories
that indicated change and comparatively weaker in groups
that indicated no change or worse change.
The post hoc nature of this study posed some chal-
lenges. Analyses were confined to the instruments col-
lected as part of the clinical trials and were not included
for the purposes of conducting a validation study. Thus,
some aspects of the instruments used to validate the
PSQ may not have been ideal. For example, items on
some instruments are not directly related to sleep or are
confounded by sleep. Finally, the recall periods varied
among the instruments and some instruments were not
specifically designed for RLS.
Conclusions
The PSQ demonstrated acceptable measurement proper-
ties of convergent validity, divergent validity, and
known-group validity. PSQ scores were also reliable in
terms of being responsive to change in symptoms. The
PSQ is, therefore, a psychometrically valid instrument
for assessing sleep among RLS subjects in clinical trial
settings.
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